Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A166 Versus T-DM1 in HER2-Positive Breast Cancer
NCT06968585Phase 3Active, not recruiting
- Sponsor
- Kelun-Biotech
- Start
- Jul 2023
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab botidotin in breast cancer, sponsored by Kelun-Biotech. Started Jul 2023; status: active, not recruiting.
02
Drugs
trastuzumab botidotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06968585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06968585.